ProBioGen appoints Dr Simon Johannes Bulling as its new Chief Operating Officer
Bulling brings extensive experience across the biopharma and CDMO landscape, with leadership roles spanning both drug substance and drug product operations
Bulling brings extensive experience across the biopharma and CDMO landscape, with leadership roles spanning both drug substance and drug product operations
Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025
Coordinated by the Medical University of Vienna, a consortium of 13 leading European organizations including university hospitals, research institutions and healthcare companies will conduct the 5-year project co-funded by Horizon Europe.
Subscribe To Our Newsletter & Stay Updated